TickerFacts.

Compare

AbCellera Biologics Inc. vs CytomX Therapeutics, Inc. vs Bicycle Therapeutics PLC vs Assembly Biosciences, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAbCellera Biologics Inc.
ABCL		CytomX Therapeutics, Inc.
CTMX		Bicycle Therapeutics PLC
BCYC		Assembly Biosciences, Inc.
ASMB
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$75.13M$76.20M$72.59M$72.30M
Revenue growth (YoY)+160.6%-44.8%+105.8%+153.5%
Gross marginn/an/an/an/a
Operating margin-289.0%-29.3%-340.4%-16.8%
Net margin-194.9%-22.8%-301.7%-8.5%
Net income-$146.41M-$17.37M-$218.96M-$6.12M
EPS (Diluted)-$0.49n/a-$3.16-$0.55
Operating cash flow-$131.29M-$75.59M-$249.68M-$41.09M
Free cash flow-$174.07M-$75.81M-$252.03M-$41.16M
Cash & equivalents$128.51M$12.67M$628.11M$58.45M
Total assets$1.36B$151.57M$717.60M$257.59M
Total liabilities$390.05M$52.56M$107.62M$50.84M
Shareholders' equity$966.90M$99.01M$609.98M$206.75M
Return on year-end equity-15.1%-17.5%-35.9%-3.0%
Shares outstanding300.60M170.19M69.37M15.86M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAbCellera Biologics Inc.CytomX Therapeutics, Inc.Bicycle Therapeutics PLCAssembly Biosciences, Inc.
Latest$75.13M
Ended 2025-12-31		$76.20M
Ended 2025-12-31		$72.59M
Ended 2025-12-31		$72.30M
Ended 2025-12-31
1 year earlier$28.83M
Ended 2024-12-31		$138.10M
Ended 2024-12-31		$35.27M
Ended 2024-12-31		$28.52M
Ended 2024-12-31
2 years earlier$38.02M
Ended 2023-12-31		$101.21M
Ended 2023-12-31		$26.98M
Ended 2023-12-31		$7.16M
Ended 2023-12-31
3 years earlier$485.42M
Ended 2022-12-31		$53.16M
Ended 2022-12-31		$14.46M
Ended 2022-12-31		$0
Ended 2022-12-31
4 years earlier$375.20M
Ended 2021-12-31		$37.31M
Ended 2021-12-31		$11.70M
Ended 2021-12-31		$6.25M
Ended 2021-12-31